Carisma Therapeutics enters up to $100M ATM equity offering through Jefferies, replacing prior $97.8M capacity

Carisma Therapeutics Inc.

May offer and sell common stock with aggregate offering price up to $100 million via Jefferies as sales agent.
Commission of up to 3% of gross proceeds; Jefferies will use commercially reasonable efforts.
A&R Sale Agreement replaces original 2019 agreement; prospectus supplement filed under effective shelf registration.
Prior remaining capacity of ~$97.8M from earlier prospectus supplements is superseded.
Company may suspend or terminate offering at any time; shares sold at market prices under Rule 415.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Carisma Therapeutics Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at up to $100.0 million (effective 2023-05-12).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $100.0 million
Effective: 2023-05-12

Exact text from the filing

On May 12, 2023, Carisma Therapeutics Inc. (the “ Company ”), entered into an Amended and Restated Open Market Sale Agreement SM (the “ A&R Sale Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Shares ”), from time to time through Jefferies. The Company has also filed a prospectus supplement (the “ Prospectus Supplement ”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-271295) that was originally filed with the Securities and Exchange Commission (the “ SEC ”) on April 17, 2023 and declared effective by the SEC on May 2, 2023 (the “ Registration Statement ”). Pursuant to the Prospectus Supplement, the Company may offer and sell Shares having an aggregate offering price of up to $100.0 million.

View on SEC.gov

Browse all material agreements →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-059849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.